# LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lba2-sintilimab-plus-bevacizumab-biosimilar-vs-sorafenib-as-first-line-treatment/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Zhenggang Ren,Jia Fan,Jian Xu,Yuxian Bai,Anjian Xu,Shundong Cang,Chengyou Du,B. Liu,Q. Li,Yi Lu,Y. Chen,Guoliang Shao,Y B Guo,Zewen Chen,Yue Yang,M. Chen,Y. Wang,Hui Zhou |
| Citations | 32 |
| DOI | 10.1016/j.annonc.2020.10.134 |
| Fields | Biochemistry, Genetics and Molecular Biology,Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3110482332 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Yue Yang](https://scholariq.org/researchers/yue-yang/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Paper topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Cancer Research and Treatments](https://scholariq.org/topics/cancer-research-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.